DE68921364D1 - Process for the production of proteins using recombinant DNA. - Google Patents

Process for the production of proteins using recombinant DNA.

Info

Publication number
DE68921364D1
DE68921364D1 DE68921364T DE68921364T DE68921364D1 DE 68921364 D1 DE68921364 D1 DE 68921364D1 DE 68921364 T DE68921364 T DE 68921364T DE 68921364 T DE68921364 T DE 68921364T DE 68921364 D1 DE68921364 D1 DE 68921364D1
Authority
DE
Germany
Prior art keywords
proteins
production
recombinant dna
host cell
synthesised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921364T
Other languages
German (de)
Other versions
DE68921364T2 (en
Inventor
Raymond John Owens
Gregory Paul Winter
Lutz Riechmann
Geoffrey Thomas Yarranton
Mark William Bodmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27263864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68921364(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB888809050A external-priority patent/GB8809050D0/en
Priority claimed from GB888811342A external-priority patent/GB8811342D0/en
Priority claimed from GB888820284A external-priority patent/GB8820284D0/en
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of DE68921364D1 publication Critical patent/DE68921364D1/en
Application granted granted Critical
Publication of DE68921364T2 publication Critical patent/DE68921364T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides a method for producing Fv fragments comprising: transforming a eukaryotic host cell with a eukaryotic expression vector comprising an operon having a DNA sequence which encodes the variable domain only of an antibody light or heavy chain, culturing the transformed host cell under conditions which cause the protein encoded by the DNA sequence to be synthesised; and collecting the synthesised protein.
DE68921364T 1988-04-16 1989-04-17 Process for the production of proteins using recombinant DNA. Expired - Fee Related DE68921364T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB888809050A GB8809050D0 (en) 1988-04-16 1988-04-16 Expression of antibody heavy & light chain variable domains as an fv-fragment
GB888811342A GB8811342D0 (en) 1988-05-13 1988-05-13 Expression of antibody heavy & light chain variable domains as active hetero-dimer in myeloma cells
GB888820284A GB8820284D0 (en) 1988-08-26 1988-08-26 Method for producing recombinant dna proteins

Publications (2)

Publication Number Publication Date
DE68921364D1 true DE68921364D1 (en) 1995-04-06
DE68921364T2 DE68921364T2 (en) 1995-06-29

Family

ID=27263864

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921364T Expired - Fee Related DE68921364T2 (en) 1988-04-16 1989-04-17 Process for the production of proteins using recombinant DNA.

Country Status (9)

Country Link
EP (1) EP0338745B1 (en)
JP (2) JP3105898B2 (en)
AT (1) ATE119198T1 (en)
AU (1) AU627183B2 (en)
CA (1) CA1341411C (en)
DE (1) DE68921364T2 (en)
ES (1) ES2070172T3 (en)
GR (1) GR3015248T3 (en)
WO (1) WO1989009825A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT92900A (en) * 1989-01-24 1990-07-31 EXPRESSION VECTOR SYSTEM FOR THE PRODUCTION OF QUIMERIC MONOCLONAL ANTIBODIES
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (en) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
JPH11513669A (en) * 1995-10-13 1999-11-24 アメリカ合衆国 Immunotoxins containing disulfide-stabilized antibody fragments
AU7288196A (en) * 1995-10-20 1997-05-15 Ciba-Geigy Ag Process for the preparation of a single chain fv antibody fragment
JP4503706B2 (en) 1996-06-07 2010-07-14 ポニアード ファーマシューティカルズ，インコーポレイティド Humanized antibodies with modified glycosylation
JP2000164361A (en) 1998-11-25 2000-06-16 Tdk Corp Organic el element
JP2003520195A (en) 1999-05-14 2003-07-02 イムクローン システムズ インコーポレイティド Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US6890532B2 (en) 2000-05-16 2005-05-10 Thomas Jefferson University Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
SI3031910T1 (en) 2002-02-21 2018-05-31 Institute Of Virology Slovak Academy Of Sciences Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
US7407659B2 (en) 2002-07-19 2008-08-05 Beth Israel Deaconess Medical Center Methods of diagnosing pre-eclampsia or eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
ES2527871T3 (en) 2003-05-01 2015-02-02 Imclone Llc Fully human antibodies directed against human insulin-like growth factor 1 receptor
US7598350B2 (en) 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
KR20130119506A (en) 2004-09-24 2013-10-31 베스 이스라엘 데코니스 메디칼 센터 Methods of diagnosing and treating complications of pregnancy
ES2523457T3 (en) 2004-11-18 2014-11-26 Imclone Llc Antibodies against vascular endothelial growth factor receptor 1
WO2006083355A2 (en) 2004-11-19 2006-08-10 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
DK2100614T3 (en) 2005-06-17 2013-10-28 Imclone Llc Antibody to PDGFR-alpha for use in the treatment of tumors
DK1919954T3 (en) 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
BRPI0714871A2 (en) 2006-07-18 2013-05-07 Sanofi Aventis antagonist antibody for cancer treatment
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR100883430B1 (en) 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof
EP3354662B1 (en) 2007-08-29 2020-08-19 Sanofi Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PE20091679A1 (en) 2008-03-12 2009-11-04 Imclone Llc ANTI-TYRP1 ANTIBODY
JP5611210B2 (en) 2008-09-07 2014-10-22 グリコネックス インコーポレイテッド Anti-expanded type I glycosphingolipid antibodies, derivatives and uses thereof
WO2011022472A2 (en) 2009-08-18 2011-02-24 President And Fellows Of Harvard College Methods and compositions for the treatment of proliferative and pathogenic diseases
AR078470A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
JP5841072B2 (en) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド CD20 antibody and use thereof
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
AR080698A1 (en) 2010-04-01 2012-05-02 Imclone Llc ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
TWI700093B (en) 2011-03-16 2020-08-01 法商賽諾菲公司 Uses of a dual v region antibody-like protein
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
TWI745962B (en) 2014-06-27 2021-11-11 法商賽諾菲公司 Methods of determining whether a dose comprising a dual-v-region antibody-like protein or a fragment thereof administered to a human subject specifically binds to il-4 or il-13 within the human subject
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibodies and immunoconjugates and uses thereof
TWI808963B (en) 2017-03-22 2023-07-21 法商賽諾菲公司 Treatment of lupus using humanized anti-cxcr5 antibodies
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
TW202110881A (en) 2019-05-24 2021-03-16 法商賽諾菲公司 Methods for treating systemic sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE64618T1 (en) * 1982-03-15 1991-07-15 Schering Corp HYBRID DNA, BINDING COMPOSITION MADE THEREOF AND METHOD THEREOF.
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (en) * 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.

Also Published As

Publication number Publication date
JP3105898B2 (en) 2000-11-06
GR3015248T3 (en) 1995-06-30
AU627183B2 (en) 1992-08-20
EP0338745A1 (en) 1989-10-25
JPH03500005A (en) 1991-01-10
CA1341411C (en) 2002-12-17
ES2070172T3 (en) 1995-06-01
WO1989009825A1 (en) 1989-10-19
ATE119198T1 (en) 1995-03-15
JPH11225758A (en) 1999-08-24
EP0338745B1 (en) 1995-03-01
DE68921364T2 (en) 1995-06-29
AU3536489A (en) 1989-11-03

Similar Documents

Publication Publication Date Title
DE68921364T2 (en) Process for the production of proteins using recombinant DNA.
DE3486179D1 (en) METHOD FOR PRODUCING MULTI CHAIN POLYPEPTIDES OR PROTEINS.
DE3587524D1 (en) PRODUCTION OF CHIMERIC ANTIBODY.
ATE87659T1 (en) BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
ATE46536T1 (en) PROCESS FOR THE PRODUCTION OF MATURE PROTEINS IN VERTEBRATE WIRCELLS.
ATE553125T1 (en) PRODUCTION OF A MULTIMERIC PROTEIN BY CELL FUSION PROCESS
DE3855084T2 (en) Production and purification of a protein fused to a binding protein
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
FI102383B1 (en) Method and plasmid for producing a modified hybrid protein containing the PE40 domain
ATE123068T1 (en) METHOD FOR PRODUCING A PROTEIN BY YEAST USING AN INDUCIBLE SYSTEM, VECTORS AND CORRESPONDING TRANSFORMED STRAINS.
DE69634757D1 (en) VECTOR FOR THE EXPRESSION OF N-TERMINAL EXTENDED PROTEINS IN HEF-CELLS
ATE72458T1 (en) ASSOCIATED RIBOSOMES AND THEIR USE IN PRODUCING PROTEINS FROM CELL CULTURES.
HUP9801330A2 (en) Novel pka-binding proteins and uses thereof
ES2111537T3 (en) RECOMBINANT HUMAN PLACENTA RIBONUCLEASE INHIBITOR AND PRODUCTION METHOD.
EP0688224A4 (en) A mutant protein and methods and materials for making and using it
DE69634297D1 (en) METHOD FOR EXTENDING THE EXPRESSION OF AN INTERESTING GENE USING SOLUBLE CTLA4 MOLECULES
ATE238349T1 (en) METHOD FOR PRODUCING A SINGLE CHAIN FV ANTIBODY FRAGMENT

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee